1001383-50-1

Basic information

• Product Name: trans-4-hydroxy-L-proline methyl ester
• Synonyms: trans-4-hydroxy-L-proline methyl ester
• CAS NO: 1001383-50-1
• Molecular Weight: 145.158
• Mol File: 1001383-50-1.mol
• Article Data: 3

Chemical Properties

• CAS DataBase Reference: trans-4-hydroxy-L-proline methyl ester(CAS DataBase Reference)
• NIST Chemistry Reference: trans-4-hydroxy-L-proline methyl ester(1001383-50-1)
• EPA Substance Registry System: trans-4-hydroxy-L-proline methyl ester(1001383-50-1)

Safety Data

• Hazardous Substances Data: 1001383-50-1(Hazardous Substances Data)

Upstream product

• 331442-12-7 (trans)-1-[(1,1-dimethylethoxy)carbonyl]-4-hydroxy-L-proline 
• 74-88-4 methyl iodide 
• 67-56-1 methanol 
• 51-35-4 4-hydroxyproline 

Downstream Products

• 144913-58-6 1[[(4-chloro-2-fluoro-5-isopropoxy) phenyl]aminocarbonyl]-(2S)-4-trans-hydroxy-pyrrolidine-2-carboxylic acid methyl ester 
• 102195-80-2 (S)-1-tert-butyl 2-methyl 4-oxopyrrolidine-1,2-dicarboxylate 
• 203866-17-5 1-tert-butyl 2-methyl (2S)-4,4-difluoropyrrolidine-1,2-dicarboxylate 
• 126111-14-6 methyl (2S)-4,4-difluoropyrrolidine-2-carboxylate 
• 1419387-85-1 C₄₇H₅₆F₄N₄O₁₂ 
• 1419391-59-5 C₄₅H₅₄N₂O₁₀ 
• 156046-05-8 (S)-4,4-difluoroproline methyl ester hydrochloride 
• 221137-87-7 methyl N-p-methoxybenzyl-4R-t-butyldimethylsilyloxy-proline 

Relevant articles and documents

SPIRO COMPOUNDS AS HEPATITIS C VIRUS INHIBITORS

Disclosed are spiro compounds of formula (I), or stereomers, geometric isomers, tautomers, nitrogen oxides, hydrates, solvates, metabolites, pharmaceutically acceptable salts or prodrugs thereof. The compounds can be used to treat hepatitis C virus (HCV) infection or hepatitis C disease. Furthermore disclosed are pharmaceutical compositions containing the compounds and the method of using the compounds or pharmaceutical compositions in the treatment of HCV infection or hepatitis C disease.

COMPOSITIONS AND METHODS FOR THE TREATMENT OF IMMUNOMEDIATED INFLAMMATORY DISORDERS

Compositions and methods for the prevention and treatment of immunomediated inflammatory disorders, especially for those disorders associated with the respiratory tract, are provided. More particularly, a tryptase inhibitor, typically a hydroxyaroyl or hydroxyheteroaroyl substituted dipeptide, is administered. Also provided by this invention are pharmaceutical compositions, typically aerosol or topical, as well as aerosol devices for administering these compositions intranasally.